Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.

Maleimides are often used to covalently attach drugs to cysteine thiols for production of antibody-drug conjugates (ADCs). However, ADCs formed with traditional N-alkyl maleimides have variable stability in the bloodstream leading to loss of drug. Here, we report that N-aryl maleimides form stable antibody conjugates under very mild conditions while also maintaining high conjugation efficiency. Thiol-maleimide coupling and ADC stabilization via thiosuccinimide hydrolysis were accelerated by addition of N-phenyl or N-fluorophenyl groups to the ring-head nitrogen. Cysteine-linked ADCs prepared with N-aryl maleimides exhibited less than 20% deconjugation in both thiol-containing buffer and serum when incubated at 37 °C over a period of 7 days, whereas the analogous ADCs prepared with N-alkyl maleimides showed 35-67% deconjugation under the same conditions. ADCs prepared with the anticancer drug N-phenyl maleimide monomethyl-auristatin-E (MMAE) maintained high cytotoxicity following long-term exposure to serum whereas the N-alkyl maleimide MMAE ADC lost potency over time. These data demonstrate that N-aryl maleimides are a convenient and flexible platform to improve the stability of ADCs through manipulation of functional groups attached to the maleimide ring-head nitrogen.

[1]  B. Liu,et al.  Development of novel linkers to conjugate pharmacophores to a carrier antibody. , 2012, Bioorganic & medicinal chemistry letters.

[2]  Alain Wagner,et al.  Selective irreversible chemical tagging of cysteine with 3-arylpropiolonitriles. , 2014, Bioconjugate chemistry.

[3]  K. Aldape,et al.  A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.

[4]  Laurent Ducry,et al.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.

[5]  James R. Baker,et al.  Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis† †Electronic supplementary information (ESI) available: Full experimental details and characterisation. See DOI: 10.1039/c1cc11114k Click he , 2011, Chemical communications.

[6]  G. Muccioli,et al.  Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. , 2009, Journal of medicinal chemistry.

[7]  A. Karlin,et al.  Reactions of cysteines substituted in the amphipathic N-terminal tail of a bacterial potassium channel with hydrophilic and hydrophobic maleimides , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Trail.  Antibody Drug Conjugates as Cancer Therapeutics , 2013 .

[9]  M. Machida,et al.  Hydrolysis of N-Substituted Maleimides : Stability of Fluorescence Thiol Reagents in Aqueous Media , 1977 .

[10]  Herren Wu,et al.  The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. , 2009, Journal of molecular biology.

[11]  C. Anfinsen,et al.  Affinity labeling of the active site of staphylococcal nuclease. Reactions with bromoacetylated substrate analogues. , 1969, The Journal of biological chemistry.

[12]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[13]  R. Abraham,et al.  The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. , 2013, Natural product reports.

[14]  John F. Valliere-Douglass,et al.  Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. , 2012, Analytical chemistry.

[15]  D. Grainger,et al.  Comparison of hydrazone heterobifunctional cross-linking agents for reversible conjugation of thiol-containing chemistry. , 2010, Bioconjugate chemistry.

[16]  P. Senter,et al.  Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates , 2014, Nature Biotechnology.

[17]  C. Meares,et al.  Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. , 1984, Analytical biochemistry.

[18]  M. Christmann,et al.  Synthesis of 4-Maleimidobutyric Acid and Related Maleimides , 2008 .

[19]  S. Caddick,et al.  Bromomaleimide-Linked Bioconjugates Are Cleavable in Mammalian Cells , 2011, Chembiochem : a European journal of chemical biology.

[20]  G. Mooser.  N-substituted maleimide inactivation of the response to taste cell stimulation. , 1976, Journal of neurobiology.

[21]  B. Hultberg,et al.  Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. , 1993, Clinical chemistry.

[22]  Antoine Maruani,et al.  A mild TCEP-based para-azidobenzyl cleavage strategy to transform reversible cysteine thiol labelling reagents into irreversible conjugates. , 2015, Chemical communications.

[23]  T. Kitagawa,et al.  Enzyme coupled immunoassay of insulin using a novel coupling reagent. , 1976, Journal of biochemistry.

[24]  Ronald T. Raines,et al.  Catalysis of imido group hydrolysis in a maleimide conjugate. , 2007, Bioorganic & medicinal chemistry letters.

[25]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[26]  Pedro M. P. Gois,et al.  Cysteine-selective reactions for antibody conjugation. , 2014, Angewandte Chemie.

[27]  T. Sippel.  the histochemistry of thiols and disulphides. I. The use of N-(4-aminophenyl)maleimide for demonstrating thiol groups , 1973, The Histochemical Journal.

[28]  Damon L. Meyer,et al.  Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.

[29]  K. Kiick,et al.  Tunable degradation of maleimide-thiol adducts in reducing environments. , 2011, Bioconjugate chemistry.

[30]  G. Martin,et al.  Albumin: Biochemical properties and therapeutic potential , 2005, Hepatology.

[31]  P. Senter,et al.  Novel peptide linkers for highly potent antibody-auristatin conjugate. , 2008, Bioconjugate chemistry.

[32]  Frank Loganzo,et al.  Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. , 2014, Bioconjugate chemistry.

[33]  M. Sliwkowski,et al.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.

[34]  T. Sippel.  The histochemistry of thiols and disulphides. IV. Protective fixation by organomercurial-formalin mixtures , 2005, The Histochemical Journal.

[35]  S. Brocchini,et al.  A new reagent for stable thiol-specific conjugation. , 2014, Bioconjugate chemistry.

[36]  Louise Robinson,et al.  Long-term stabilization of maleimide-thiol conjugates. , 2015, Bioconjugate chemistry.

[37]  D. Liebler,et al.  Reversibility of covalent electrophile-protein adducts and chemical toxicity. , 2008, Chemical research in toxicology.

[38]  D. Philp,et al.  A simple synthetic replicator amplifies itself from a dynamic reagent pool. , 2008, Angewandte Chemie.

[39]  T. Kitagawa,et al.  Preparation and Characterization of Hetero-bifunctional Cross-linking Reagents for Protein Modifications , 1981 .